Compare FLUX & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | CDIO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.1M |
| IPO Year | 2019 | 2021 |
| Metric | FLUX | CDIO |
|---|---|---|
| Price | $0.25 | $1.77 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.87 | N/A |
| AVG Volume (30 Days) | ★ 135.5K | 16.5K |
| Earning Date | 11-03-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,317,000.00 | $14,825.00 |
| Revenue This Year | N/A | $168,534.06 |
| Revenue Next Year | $85.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.28 | $0.97 |
| 52 Week High | $1.83 | $7.91 |
| Indicator | FLUX | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 28.05 | 47.59 |
| Support Level | N/A | $1.72 |
| Resistance Level | $0.48 | $2.20 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 0.43 | 32.67 |
Flux Power Holdings Inc. designs, develops, manufactures, and sells a portfolio of lithium-ion energy storage solutions for the electrification of a range of industrial and commercial sectors, which include material handling, airport ground support equipment (GSE), and stationary energy storage. It offers a high-power battery cell management system(BMS). The BMS serves as the brain of the energy storage solution, managing cell balancing, charging, discharging, monitoring, and communication between the pack and the forklift. The company's product portfolio includes Battery Technology and Energy Management solutions.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.